H.C. Wainwright analyst Robert Burns lowered the firm’s price target on Relay Therapeutics (RLAY) to $14 from $16 and keeps a Buy rating on the shares. The firm updated the company’s model post the Q2 report.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RLAY:
- Relay Therapeutics price target lowered to $19 from $29 at Raymond James
- Relay Therapeutics Reports Q2 2025 Financial Results and Progress
- Relay Therapeutics reports Q2 EPS (41c), consensus (47c)
- Relay Therapeutics’ Phase 3 Study: A New Hope for Advanced Breast Cancer Treatment
- Relay Therapeutics has positive read from Celcuity data, says Barclays